Elmelech Idan 4

What Happened

• Elmelech Idan, COO and Principal Financial Officer of BridgeBio Oncology Therapeutics, had 343 shares of common stock withheld by the company on July 1, 2026 to satisfy tax withholding related to vested restricted stock units. The withholding price was $7.80 per share, for a total value of $2,675. This was a share surrender for tax purposes, not an open-market sale or purchase.

Key Details

• Transaction date and price: July 1, 2026 — 343 shares withheld at $7.80/share (total $2,675).
• Shares owned after the transaction: Not specified in the provided filing details.
• Footnote: F1 — shares were withheld by the issuer to satisfy the reporting person's tax withholding obligations in connection with RSU vesting.
• Filing date vs. transaction date: Form filed July 6, 2026 for a July 1 transaction. Check the Form 4 for any late-filing indicator ('L'); none was provided in the summary data here.

Context

• This transaction is a routine tax-withholding event tied to RSU vesting (a common administrative action) and does not represent an open-market sale or a directional bet by the insider. Such withholdings are standard and generally not considered a signal of insider sentiment.